Edesa Biotech (EDSA) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Edesa Biotech (EDSA) has outperformed Talphera (TLPH) over the past year, gaining 34.6% versus a loss of 18.2%. Over five years, EDSA leads with a -93.3% price change compared with -94.7% for TLPH. Talphera is the larger company by market cap ($56.1 million vs $49.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDSA | TLPH |
|---|---|---|
| Share price | $3.66 | $1.08 |
| Market cap | $49.45M | $56.06M |
| 1-day change | -5.79% | +2.86% |
| YTD return | +157.75% | -5.26% |
| 1-year return | +34.56% | -18.18% |
| 5-year return | -93.31% | -94.71% |
| EPS (TTM) | $-1.72 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.32 | $1.57 |
| 52-week low | $0.72 | $0.69 |
| Distance from 52-week high | -81.99% | -31.21% |
| Analyst consensus | none | none |
| Avg. price target upside | +346.17% | +189.81% |
| Average volume | 61.89K | 238.38K |
| Shares outstanding | 13.51M | 51.91M |
| Employees | 17 | 12 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed TLPH by 52.7 percentage points over the past year.
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Healthcare · Biotechnology · 17 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Healthcare · Drug Manufacturers - Specialty & Generic · 12 employees
EDSA vs TLPH FAQ
Which is bigger, Edesa Biotech or Talphera?
Talphera (TLPH) is larger, with a market capitalization of $56.06M compared with $49.45M for Edesa Biotech (EDSA).
Which stock has performed better over the past year, EDSA or TLPH?
EDSA returned +34.56% over the past 12 months, compared with -18.18% for TLPH (price return, excluding dividends). Past performance does not predict future results.
Are Edesa Biotech and Talphera in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Edesa Biotech and Drug Manufacturers - Specialty & Generic for Talphera.